SAHPRA registers Janssen Covid-19 vaccine with conditions

The South African Health Products Regulatory Authority (SAHPRA) announced on Monday the registration of the Janssen Covid-19 vaccine on March 31, with conditions. SAHPRA CEO Dr Boitumelo Semete-Makokotlela explained that one of the conditions is that the vaccine be manufactured under conditions of Good Manufacturing Practices (GMP) as determined by SAHPRA and aligned with global best practice.
/by
You might also like
SA turns to Mozambique’s vast natural gas reserves as Eskom battles to keep the lights on
Balancell moves into new factory, seeks strict regulations on imports
Red Rocket confirms initial 500 MW of interest in 2 000 MW virtual wheeling renewables scheme
Energy storage to reduce renewable energy intermittency concerns
Specialist awarded testing, maintenance contract
Trading, transmission key factors in a liberalised South African electricity market